This review paper analyzes the changes in the EAU guidelines for the treatment of prostate cancer from 2003 to 2023, with an emphasis on surgical methods, especially lymphadenectomy and its role in diagnosis and treatment. It also mentions progress in diagnostic possibilities (mpmr, psma pet ct), which enabled a more precise assessment of the risk and stage of the disease and a personalized approach to treatment. Furthermore, the paper shows the evolution of recommendations on the use of lymphadenectomy in the treatment of prostate cancer. While earlier guidelines recommended "limited" (obturator) lymphadenectomy only in patients at high risk of cancer spreading beyond the prostate, later guidelines increasingly emphasize the importance of pelvic lymphadenectomy as a diagnostic and therapeutic procedure in moderate- and high-risk patients. The latest 2023 guidelines provide a comprehensive overview of treatment options for prostate cancer such as radical prostatectomy, radiotherapy, hormone therapy and newer approaches such as focused ultrasound ablation (hifu). The paper also shows how active surveillance and radiotherapy are important non-surgical methods of prostate cancer treatment. In summary, this thesis provides an overview of the changes in the EAU guidelines for the treatment of prostate cancer with an emphasis on surgical methods and lymphadenectomy and analyzes non-surgical methods and the principle of systemic treatment.